Barbui, Tiziano
Tefferi, Ayalew
Vannucchi, Alessandro M. http://orcid.org/0000-0001-5755-0730
Passamonti, Francesco
Silver, Richard T.
Hoffman, Ronald
Verstovsek, Srdan
Mesa, Ruben
Kiladjian, Jean-Jacques
Hehlmann, RČ•diger
Reiter, Andreas
Cervantes, Francisco
Harrison, Claire
Mc Mullin, Mary Frances
Hasselbalch, Hans Carl
Koschmieder, Steffen
Marchetti, Monia
Bacigalupo, Andrea
Finazzi, Guido
Kroeger, Nicolaus
Griesshammer, Martin
Birgegard, Gunnar
Barosi, Giovanni
Article History
Received: 27 November 2017
Revised: 16 January 2018
Accepted: 26 January 2018
First Online: 27 February 2018
Compliance with ethical standards
:
: TB received advisory board fee from Novartis; FC received advisory board fee from Novartis, honoraria from Novartis, AOP Orphan Disease and Shire, and speaker bureau fee from Novartis, AOP and Shire; AMV received advisory board fee from Novartis, and Speaker bureau fee from Novartis and Shire; MM received speaker bureau fee from Gilead and Amgen; SK received research funding from Novartis, Bristol-Myers Squibb, and Janssen, honoraria and advisory board fees from Novartis, Incyte/Ariad, Pfizer, Bristol-Myers Squibb, Janssen, AOP, CTI, and travel support from Shire; AR received advisory board fee and honoraria from Novartis; MG received honoraria from Shire, Novartis, Baxalta, AOP Orphan Disease, Gilead and Janssen; JJK received advisory board fee and funding from Novartis and AOP Orphan; AB received honoraria form Novartis, Therakos, Sanofi and Adienne, and advisory board fee from Novartis; MFMM received honoraria and consulting fee from Novartis and Gilead; SV received support for research from: Incyte Corporation, Roche, Astra Zeneca, Lilly Oncology, NS Pharma, Bristol Mayers Squibb, Celgene, Gilead, Seattle Genetics, Promedior, CTI BioPharma Corp., Galena BioPharma, Pfizer, Genentech, Blueprint Medicines Corp.; RM received consulting fee from Novartis, AOP, Shire, and research funding from Incyte, Gilead, Pharmessential, Celgene and Promedior; R Ho received research funding from Incyte and Janssen; FP served on advisory boards for Sanofi, Gilead, Janssen Pharmaceutical, Celgene, Novartis, Bristol-Myers Squibb and Roche; GB received advisory board fee from Novartis. GF and G Bi have no conflict of interest.